Try our Advanced Search for more refined results

Perry et al v. Spectrum Pharmaceuticals, Inc. et al

  1. January 28, 2016

    Spectrum, Investors Get Preliminary OK Of $7M Settlement

    A Nevada federal judge has given preliminary approval of a $7 million settlement between Spectrum Pharmaceuticals Inc. and a class of shareholders accusing the company of not properly disclosing that a generic of its cancer drug Fusilev was about to dramatically decrease demand for the brand-name drug.

  2. March 27, 2015

    Spectrum Pharmaceuticals Stuck With Shareholder Suit

    A Nevada federal judge on Thursday denied a motion to dismiss a consolidated amended proposed class action against Spectrum Pharmaceuticals Inc. and individual defendants, saying that the plaintiffs sufficiently pled that the biopharma company made misleading statements in the context surrounding its cancer treatment drug.

  3. March 15, 2013

    Spectrum Pharmaceuticals Hit With Shareholder Class Action

    Spectrum Pharmaceuticals Inc. was hit with a putative class action in Nevada federal court Thursday, accusing the biotechnology company of misleading investors about the sales potential of cancer treatment Fusilev, causing them to pay too much for the company's stock.